Lv1
64 积分 2025-07-21 加入
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
1个月前
已完结
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
1个月前
已完结
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
1个月前
已完结
Identification of the tumour transition states occurring during EMT
1个月前
已完结
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
1个月前
已完结
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
1个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
1个月前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
1个月前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
1个月前
已完结
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
1个月前
已完结
皖公网安备34019202002308
